We are the first to investigate the impact of LLLT on the cost of treatment those patients.
We report data suggesting that morbidity was lower in the Laser Group.
The incremental cost-effectiveness ratio (ICER) was US$ 4961.37 per grade 3–4 OM case prevented compared to no treatment.
LLLT was more cost-effective than placebo.